Today: 11 June 2026
Browse Category

NYSE:CPRI 23 August 2025 - 3 December 2025

Prada Completes $1.4 Billion Versace Acquisition: What Comes Next for Italian Luxury

Prada Completes $1.4 Billion Versace Acquisition: What Comes Next for Italian Luxury

Prada Group completed its acquisition of Versace from Capri Holdings on December 2, 2025, in an all-cash deal valued between €1.25 and €1.3 billion. Versace will represent about 13% of Prada Group revenues. The deal followed regulatory approval after Capri’s failed merger with Tapestry earlier in the year. Prada funded the purchase largely through €1.5 billion in new debt.
3 December 2025
·
Prada Completes €1.25 Billion Versace Takeover, Redrawing the Global Luxury Fashion Map

Prada Completes €1.25 Billion Versace Takeover, Redrawing the Global Luxury Fashion Map

Prada Group completed its €1.25 billion ($1.4 billion) acquisition of Versace from Capri Holdings on December 2, 2025, after securing regulatory approvals. The deal is the largest in Prada’s history and adds Versace to a portfolio that includes Prada and Miu Miu. Versace accounted for about 20% of Capri’s 2024 revenue. Prada heir Lorenzo Bertelli will serve as Versace’s executive chairman.
2 December 2025
·
2025’s Most Popular Men’s and Women’s Watches – Luxury Icons, Smartwatch Superstars, Fashion Favorites & Affordable Gems

2025’s Most Popular Men’s and Women’s Watches – Luxury Icons, Smartwatch Superstars, Fashion Favorites & Affordable Gems

Swiss watch exports hit a record CHF 26.7 billion in 2023. Rolex surpassed CHF 10 billion in annual revenue, selling about 1.24 million watches and capturing 30% of the market. The Big Four brands account for nearly 44% of Swiss watch market value. Smartwatches reached 455 million users worldwide, with Apple holding a 21% share.
23 August 2025
······

Stock Market Today

  • How to Invest Indirectly in SpaceX Before IPO Through ETFs
    June 11, 2026, 10:46 AM EDT. Investors can gain indirect exposure to SpaceX ahead of its IPO via ETFs like ERShares Private-Public Crossover ETF (XOVR) and AGIX. These funds use special purpose vehicles (SPVs)-legal entities holding SpaceX shares-to navigate SEC rules allowing up to 15% allocation in illiquid private companies. XOVR holds about 13.2% exposure to SpaceX through SPVs, while AGIX combines SPV investments with a small direct stake. Investors should note these ETFs are thematic portfolios with broad tech focuses and relatively high expense ratios. Direct public investment remains available only after SpaceX's Nasdaq debut at ticker SPCX on June 12, priced around $135, targeting a $1.75-$2 trillion valuation.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop